Why the study?
Whether finerenone-induced change in urine albumin-to-creatinine ratio mediates cardiovascular and kidney failure outcomes in patients with CKD and T2D was unknown.
Does finerenone-induced albuminuria reduction mediate the treatment effect on kidney and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes?
Population
12 512 patients with CKD and T2D across 48 countries
Comparison
Finerenone vs placebo
Design
Post hoc mediation analysis of pooled data from 2 phase 3, double-blind trials
Follow-up
4-year period
Authors
Loading...
Supports albuminuria reduction mediating most finerenone kidney benefit in CKD with T2D; hypothesis-generating for cardiovascular mechanisms.
Does finerenone-induced albuminuria reduction mediate the treatment effect on kidney and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes?
In patients with CKD and T2D, early albuminuria reduction by finerenone mediates a large proportion of its kidney protective effects and a modest proportion of its cardiovascular benefits.
Agarwal et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: